BioAlliance Pharma Announces Two New Key Steps in the Development of Its AMEPĀ® Biotherapy  
4/26/2012 11:05:46 AM

PARIS--(BUSINESS WIRE)--Regulatory News: BioAlliance Pharma SA (Euronext Paris - BIO), a company dedicated to orphan oncology products and specialty products, today announces the validation by the French drug agency (Afssaps) of its application for a phase I/II clinical trial with AmepĀ® in the metastatic melanoma, and the signature of a partnership agreement for the development of its biotherapy with the Department of Oncology of the Herlev Hospital of Copenhagen.